

Breast Cancer Screening

Dr Richard Chisholm Radiologist, Christchurch Clinical Director BreastScreen South Ltd






- Started Dec 1998
- Government funded
- Age range 50 64 yrs
- Age extension July 2004: 45 69 yrs
- Eligible women 628,015 (2010)
- Cost per woman screened NZD 194 including admin
 NZD 171 paid to Lead Provider
 Cost per cancer detected NZD 37, 690



Lead Provider	Eligible Pop (2010)
BSWN	102,770
BSAL	59,120
BSCM	61,960
BSM	99,170
BSCtoC	82,550
BSC	67,440
BSL	110,680
BSHC	44,325
BSA TOTAL	628,015

BSA Lead Provider Regions

Breast Screen Aotearoa





Mobile Bus



10-35% of women are screened on a mobile bus




Population Coverage July 07 – June 09

Age	Percent	Range
50 – 69 yrs	65%	53 – 80%
45 – 49 yrs	59%	48 – 88%

Target all age groups - 70%



Coverage by Ethnicity July 07 – June 09



Maori 52% Range: 42 – 74%



Pacific 56%

46 - 79%




Other 67%

52 - 80%

Target all ethnicities – 70%

BreastScreen South Ltd



INVITATION

MAMMOGRAPHY TRUST

GREY HOSPITAL



Identify eligible population and set sub-contractor targets

General practice based (64%)


0800 number self enrolment (36%)

Health promotion - Maori and Pacific Island

Success

- GP Co-ordinators 70% target
- Payment to general practices
- Stand alone structure

Referral of Patients to BreastScreen South or Private/Public Provider



BreastScreen Aotearoa (BSA) National Screening Programme • Asymptomatic women aged 45-

•Have not had a mammogram in the last 12 months (may enrol in the interim but will not be screened until 12 months have elapsed) •Non-pregnant and 3 months post cessation of lactation.

•If previous breast cancer, eligible to rejoin 5 years post diagnosis.

•NZ citizen or immigration permit for 2 or more years stay.

GP (with woman's informed consent)

BreastScreen South Ltd Ph: 0800 270 200 or 03 379 2411


(Screening appt will be generated/offered for appropriate screening location: Canterbury BreastCare, After Hours Radiology, Cashmere Radiology, Nelson Radiology, Wairau Hospital, South Canterbury Mammography, Greymouth Mammography Unit or Mobile Screening Unit)

NB: BSA is not able to assess women who have a significant symptom (eq new lump, thickening, puckering or dimpling of skin, any change to one nipple, or other new symptoms).



Screening Process

Mediolateral oblique and craniocaudal view each breast



Two yearly – 45 to 69 years Analogue or Digital Mammography



Population and MRTs





Screening Process

Batch reading At least two radiologists





Screen Reading Radiologist





Recalled to Assessment July 07 – June 09

	Initial 9	%	Subseq	uent %
	45-49	50-69	45-49	50-69
Recalled to Assess	9.3	9.8	4.1	3.0
BSL	7.3	7.1	4.1	2.9
Target Desired		<10 <7		<5 <4
Positive Predictive Value BSL Target	5.5* 5.9*	9.7 10.4 ≥9	7.6* 6.6*	18.3 18.0 ≥9



Radiologist at Assessment





Assessments – BSL July 07 – June 09

Number of Women Assessed 3348

Surgical Opinion
 Needle Biopsy
 FNA
 Core (U/S)
 Core (Stereo)
 Open Biopsy

435 13% of Recalls
 1017 30.4% of Recalls
 30 0.9% of Recalls
 560 16.7% of Recalls
 427 12.8% of Recalls
 49 1.5% of Recalls
 0.05% of Screens



Early Detection of DCIS or Invasive Breast Cancer July 07 – June 09

Age		R	ate per	1000 sc	reens
(years)	Initial	BSL	Subse	equent	BSL
45 – 49	5.1*	4.3*	3.1*		2.7*
50 – 69 Target	9.4 ≥ 6.9	7.3	5.6 ≥ 3.4	ŀ5	5.2

DCIS = 23.4% of all Screen Detected Cancers Target 10 – 25%



Small Invasive Cancers July 07 – June 09

	Initial ≤10mm	Subsequent ≤10mm	Initial <15mm	Subsequent <15mm
45-49	25.8	25.6*	40.4*	43.9*
50-69	28.0	39.9	41.7 *	58.5
Target	≥25%	≥ 30%	>50%	>50%
No. / 10,000 screens				
45-49	8.8*	5.5*	13.9*	9.5*
50-69	19.6	16.8	29.3*	24.6
Target	≥17.3	≥10.45	>34.5	>17.3



Lymph Node Involvement

Node negative invasive screen detected cancers

 45-49
 50-69

 Initial
 71%
 74%
 Target > 70%

 Subsequent
 65%*
 78%
 Target > 75%



Provision of Appropriate and Acceptable Service

	BSA (%)	BSL (%)	Target
Informed of Screening result within 10 working days	95	98	90/95%
Offered first assessment appointment within 15 working days of screening	79 *	94	90%
Receiving needle biopsy within 5 working days of assessment	90	87*	≥90%
Having open biopsy within 20 working days of being informed of need	72 *	96	≥90%
Receiving final diagnostic biopsy results within 5 working days	87 *	93	≥90%
Receiving surgical treatment within 20 days of final diagnostic result	64 *	72 *	90%

Multidisciplinary Telelink BSL





Does screening mammography work?

- > 7 main prospective randomised controlled trials
- Most started at 40 years age
- 5 showed reduced mortality
- 2 showed reverse

Meta-analysis of data from all 7 trials:

- > 24% reduction in mortality from breast cancer
- ▶ 30% reduction for those women screened
- Compliance not complete. Screened and control groups.

Ref:- Why the critics of screening mammography are wrong "They distort data, rely on weak science, but refuse to defend when challenged" Kopans, D. B. *Diagnostic Imaging* Vol. 31 No. 12 December 4, 2009 (Professor of Radiology, Harvard Medical School)

Radiation Risk of Mammography (Medical Physicist)

170:1

110:1

Stochastic effect	-	Latent period 5 – 10 years
Age-related	-	Age 30 risk 3-4 x greater than 50

Net benefit of screening Number of detected cancers vs. number of induced Number of lives saved

Dose

Mammogram Equivalent to 0.6mSv
15 weeks background irradiation
5 return flights to UK

Risk

1 in 100,000 risk of death Equivalent to - 1

- 15,000 km flying
- 1000 km driving
- 150 km cycling
- 3 weeks L.A. smog
- 5 bottles of wine
- 4 months as a radiologist
- 60 year old male for 3 hours




Cancers found in BreastScreen Aotearoa

Size of the smallest cancer found by regular mammography (2mm) Average size of cancer found by regular mammography (14.5mm) Average size of cancer found by a first mammogram (15.6mm)

Average size of a cancer found by chance (22mm)

Screening Ultrasound

- Operator dependant
- Yield 3 to 4 cancers per 1000
- Limited DCIS detection
- Double biopsy rate compared with cf mammography



Thermography

The National Screening Unit (NSU), the Cancer Society of New Zealand and The New Zealand Breast Cancer Foundation do not support the use of thermography as a breast cancer screening or diagnostic tool as there is insufficient evidence to do so.

Position Statement "The use of thermography as a breast cancer screening or diagnostic tool" January 2005

Screening High Risk

<u>High Risk</u>

- BRCA 1 or 2 mutation carrier or 1st degree relative (untested)
- Chest RTH age 10-30 (after 8 years)
- \geq 20% lifetime risk (various models)

Protocol:

Begin annual mammography and MRI (US if unable) at 30 (25 BRCA)

33%

48%

93%

100%

Sensitivity (Kuhl et al) n = 1679 annual screen high risk 27 cancers found

Mammography Mammography and Ultrasound MRI Mammography & Ultrasound & MRI

Screening Intermediate and Average Risk

Intermediate Risk

- Previous breast cancer, LCIS, ALH, ADH
- Lifetime risk 15-20%
- Dense breasts

Protocol:

- Annual mammography
- Begin 10 years before family member (not before 30)
- Optional MRI or US

<u>Average Risk</u>

- Annual mammography 40-50 years
- 2 yearly mammography 50+

Stop Screening

- 5-7 years before life expectancy
- MRI 59 years. US continue.

The End





Small Invasive Cancers July 07 – June 09

	Initial ≤10mm	Subsequent ≤10mm	Initial <15mm	Subsequent <15mm
45-49	25.8% (30.6%)	25.6% (16.0%)	40.4% (44.4%)	43.9% (32.0%)
50-69	28.0% (30.0%)	39.9% (38.3%)	41.7% (50.0%)	58.5% (63.7%)
Target	≥25%	≥ 30%	>50%	>50%
No. / 10,000 screens 45-49				
	8.8 (9.9)	5.5 (3.1)	13.9 (14.4)	9.5 (6.2)
50-69	19.6 (16.3)	16.8 (15.2)	29.3 (27.1)	24.6 (25.3)
Target	≥17.3	≥10.45	>34.5	>17.3



Lymph Node Involvement

Node negative invasive screen detected cancers

	45-49	50-69	
Initial	71%	74%	Target > 70%
(BSL)	(64%*)	(75%)	
Subsequent	65% *	78%	Target > 75%
(BSL)	(60%*)	(79%)	



Recalled to Assessment July 07 – June 09

50-69 Year Old Women

	Initial	Subsequent
Recalled to Assess	9.8	3.0
BSL	7.1	2.9
Target	<10	<5
Desired	<7	<4
Positive Predictive Value	9.7	18.3
BSL	10.4	18.0
Target	≥9	≥9



Assessment Data July 07 – June 09

Preoperative Diagnosis of Malignancy – 95% BSL – 98% Target > 90% Desired >70% Expected

Benign Open Biopsy Rate Initial (Prevalent) 1.9 per 1000

Subsequent (Incident) 0.5 per 1000

BSL0.9 per 1000Target \leq 3.5 per 1000screens

0.3 per 1000 ≤ 1.6 per 1000 screens



Recalled to Assessment July 07 – June 09

45-49 Year Old Women

	Initial	Subsequent
Recalled to Assess	9.3	4.1
BSL	7.3	4.1
Target	<10	<5
Desired	<7	<4
Positive Predictive Value	5.5	7.6
BSL	5.9	6.6
Target	≥9	≥9



Staff Numbers

Lead Provider	MRTs	Radiologists	Breast Nurses	Surgeons	Pathologists
BSL	27	15	4	16	3
BSWN	18	12	3	6	6
BSM	15	13	2	4	3
BSCtoC	15	7	3	9	3
BSC	13	5	3	4	4
BSCM	8	4	2	6	9
BSAL	11	6	2	6	3
BSHC	11	5	4	3	3
TOTAL	118	67	23	54	34

Average screen detected cancers per annum in BSA = 1100 (approx)



Interval Cancers – BSL

Presented within first year from Screen: 0.58 per 1000 screens Target: <0.69 per 1000 screens

Presented within second year from Screen:

- > 0.92 per 1000 screens
- > Target: <1.2 per 1000 screens